A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Inclusion Criteria: * Subjects of either gender aged ≥ 50 years * Active subfoveal choroidal neovascularization (CNV) secondary to AMD * Presence of sub-retinal hyper-reflective material (SD-OCT) Exclusion Criteria: * Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral supplements of vitamins and minerals * Any prior intravitreal treatment in the study eye prior to the Day 1 visit, regardless of indication (including intravitreal corticosteroids) * Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication * Subjects with subfoveal scar or subfoveal atrophy are excluded * Diabetes mellitus